Yasuhito Nannya
Prof Yasuhito Nannya, MD, PhD is an expert in Hematology at Clinical Research Tokyo Hospital (Japan). As of November 2026, ScienceLeadR ranks Yasuhito Nannya in the top 1% of experts in Japan for Leukemia. Yasuhito Nannya has authored 532 publications, the most recent in 2026, and is an investigator in 1 clinical trial, 1 of them ongoing. SLR score: 1,385 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Oncology - Genetics - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026University of Tokyo - Professor
2004 - 2026
Kyoto University - Program oriented professor
2016 - 2026
Tokyo Metropolitan Institute of Medical Science
2021 - 2026
Clinical Research Tokyo Hospital
2021 - 2026
California Institute Of Medical Science
2022 - 2026
Nihon Institute of Medical Science
2023 - 2026
Number : 532
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clinical spectrum and hematopoietic stem cell transplantation outcomes in Japanese patients with GATA2 deficiency. PMID 43013244 — cells, blood, microscopy, electron, scanning transmission, hematopoietic stem cell transplantation, gata2 deficiency, stem cells, cell transplantation, stem cell transplantation, hematopoietic stem cells, hematologic diseases, transplantation | Int J Hematol | 2026 | 0 |
| Nodal T Follicular Helper Cell Lymphoma With Epstein-Barr Virus-Positive Neoplastic T Cells Derived From Clonal Hematopoiesis. PMID 42959303 — cells, hematopoiesis, bone marrow, lymphoma, clonal hematopoiesis, herpesvirus 4, human, viruses, mutation, t-lymphocytes, helper-inducer | EJHaem | 2026 | 0 |
| Inflammasome activation promotes the progression of myelodysplastic syndrome. PMID 42946195 — myelodysplastic syndromes, bone marrow, hematology, phenotype, inflammasomes, leukemia, leukemia, myeloid, acute, caspases, leukemia, myeloid, research | Exp Hematol | 2026 | 0 |
| Passive acquisition of hepatitis B virus antibodies after allogeneic hematopoietic cell transplantation. PMID 42902498 — hepatitis b surface antigens, cells, research design, blood, hepatitis b virus, hepatitis b antibodies, antibodies, immunoglobulins, herpesvirus 1, cercopithecine, viruses, cell transplantation, blood platelets, hepatitis b, transplantation, infections, hepatitis | Transfusion | 2026 | 0 |
| Flow cytometric assessment of T-cell receptor β-chain constant region 1/2 skewing as a surrogate marker for clonality in human T-cell leukaemia virus type-1-infected cells. PMID 42885517 — cells, flow cytometry, hematology, viruses, t-lymphocytes, receptors, antigen, t-cell | Br J Haematol | 2026 | 0 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 3
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes NCT05436587 — bone marrow failure disorders, research design, bone marrow, pancytopenia, chromosome fragility, phenotype, congenital bone marrow failure syndromes, biopsy, exome, exome sequencing, mutation, universities | N/A | Recruiting | 2022 |
LeadR Networks
Main global connection map